PBC Ireland - Publications

Takeuchi A, et al. 2026. Stability and Variability of Symptom Burden in Primary Biliary Cholangitis: Insights From a Decade of Follow-Up. Hepatol Res (Jul 2026)

Khamis F, et al. 2026. Suboptimal response to ursodeoxycholic acid among patients with primary biliary cholangitis and fenofibrate as add-on therapy: a single-centre retrospective study. Singapore Med J (Jul 2026)

Moriya K, et al. 2026. Glucosyl hesperidin benefits in primary biliary cholangitis: a multicenter, open-label, randomized controlled study. Clin Transl Gastroenterol (Jul 2026)

Assis DN. 2026. Delphi Consensus in Primary Biliary Cholangitis: Collective Introspection to Set a Forward Path. J Hepatol (Jul 2026)

Tanigawa R, et al. 2026. Pemafibrate Improves Cholestatic Markers Regardless of the Presence of Primary Biliary Cholangitis. Hepatol Res (Jul 2026)

Syed H, et al. 2026. Machine Learning Predicts Treatment Response and Prognostic Pathways From Whole-Blood Transcriptome in Primary Biliary Cholangitis. Liver Int (Aug 2026)

Bowlus CL, et al. 2026. Long-Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long-Term Safety Extension. Aliment Pharmacol Ther (Jul 2026)

Chen Z, et al. 2026. Integrative Analysis of Genetic and Cellular Interactions Connecting Inflammatory Bowel Disease and Primary Biliary Cholangitis. Clin Res Hepatol Gastroenterol (Jul 2026)

Aronsohn F, Poniachik J. 2026. [Hepatic Overlap Syndrome: Primary Sclerosing Cholangitis and Primary Biliary Cholangitis. Case Review]. Rev Med Chil (Apr 2026)

Juskova I, et al. 2026. Primary biliary cholangitis: Beyond classical histopathology - diagnostic challenges in native and transplanted livers. Ann Diagn Pathol (Jul 2026)

Levy C, et al. 2026. Qualitative Evaluation of Fatigue and Pruritus Among Patients with Primary Biliary Cholangitis. Adv Ther (Jul 2026)

Su M, et al. 2026. Neutrophil extracellular traps drive cholangiocyte injury via ZNF709-TP53-MDM2 pathway in primary biliary cholangitis. Hepatol Int (Jul 2026)

He C, et al. 2026. Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open-Label Randomized Clinical Trial. J Gastroenterol Hepatol (Jul 2026)

Tan JJ, et al. 2026. Hepatic and Cardiovascular Outcomes in Primary Biliary Cholangitis With Metabolic-Dysfunction Associated Steatotic Liver Disease. Liver Int (Aug 2026)

Mirowski K, et al. 2026. Environmental shaping of tolerance failure in autoimmune liver diseases: a phenotype-specific framework with primary biliary cholangitis as the strongest model. J Transl Autoimmun (Dec 2026)

Alamgir M, et al. 2026. A Review of Therapies for Primary Biliary Cholangitis. Gastroenterol Hepatol (N Y) (Jul 2026)

Ran Y, et al. 2026. [Dietary serine supplementation inhibits the hepatic macrophage AKT/mTOR pathway and improves primary biliary cholangitis]. Zhonghua Gan Zang Bing Za Zhi (Jun 2026)

Crittenden DB, Hirschfield GM. 2026. Letter: Assessing Pruritus Efficacy With Peroxisome Proliferator-Activated Receptor Agonists in Primary Biliary Cholangitis Must Include Grading the Strength of Trial Evidence. Aliment Pharmacol Ther (Jun 2026)

Qianlang R, et al. 2026. Gut microbiota alterations in primary biliary cholangitis: a systematic review and meta-analysis. Front Microbiol (2026)

Liu T, et al. 2026. Monocyte-Derived Macrophage Ferroptosis Amplifies Cholangitis in Primary Biliary Cholangitis via a Calpain/ACSL4 Axis. Biomedicines (May 2026)

Ortega-Torres A, et al. 2026. Primary biliary cholangitis mortality in Europe: a temporal and spatial view across the period 2002-2022. BMC Public Health (Jun 2026)

Abadi-Ron VE, et al. 2026. Current Treatment of Primary Biliary Cholangitis and Primary Sclerosing Cholangitis: A Comprehensive Review. Turk J Gastroenterol (Jun 2026)

Njei B, Sidney Kanmounye U. 2026. An Explainable AI Framework for Continuous Monitoring, Risk Stratification, and Clinical Decision Support in Primary Biliary Cholangitis: Protocol for a Multiphase Development and Validation Study. JMIR Res Protoc (Jun 2026)

Zheng M, et al. 2026. Prognostic nutritional index as a predictor of ursodeoxycholic acid response in primary biliary cholangitis: a retrospective study. BMC Gastroenterol (Jun 2026)

Sousa JM, et al. 2026. Prevalence and incidence of chronic kidney disease in patients with primary biliary cholangitis. J Gastroenterol (Jun 2026)

Rogalska M, et al. 2026. Circulating matrix metalloproteinase profile in early-stage primary biliary cholangitis. Sci Rep (Jun 2026)

Li S, et al. 2026. Letter: A Histology-Defined Triple-Negative Phenotype of Primary Biliary Cholangitis. Aliment Pharmacol Ther (Jun 2026)

Yan Y, et al. 2026. Folate deficiency correlates with severity of primary biliary cholangitis via modulating key regulatory genes. Front Nutr (2026)

Yamashita Y, et al. 2026. Baseline and Longitudinal Liver Stiffness Measurement Predict Outcomes in Primary Biliary Cholangitis: A Multicenter Study. Hepatol Res (Jun 2026)

Awan MA. 2026. AMA-Positive Cholestasis in Celiac Disease: Why Primary Biliary Cholangitis Should Not Be Excluded by Biopsy Alone. Clin Case Rep (Jun 2026)

Kanda T, et al. 2026. Linerixibat reduces cholestatic pruritus in patients with primary biliary cholangitis. Transl Gastroenterol Hepatol (2026)

Palomer X, et al. 2026. The emerging role of PPARs in primary biliary cholangitis. Trends Mol Med (Jun 2026)

Franke A, et al. 2026. Misclassification of UDCA treatment response in patients with primary biliary cholangitis (PBC) in the real-world setting. Ann Hepatol (Jun 2026)

Hayashi M, et al. 2026. Utility of pretreatment GLOBE score as a non-invasive prognostic tool in primary biliary cholangitis. Immunol Med (Jun 2026)

Hanatani T, et al. 2026. [A case of primary biliary cholangitis whose pathology changed during autoimmune hepatitis]. Nihon Shokakibyo Gakkai Zasshi (2026)

Werner E, et al. 2026. Bezafibrate for primary biliary cholangitis: A number needed to treat analysis. JHEP Rep (Jun 2026)

Huang M, et al. 2026. Glasgow Prognostic Score Predicts Hepatic Recompensation in Decompensated Primary Biliary Cholangitis: A Multicenter Cohort Study. J Inflamm Res (2026)

Zhang J, et al. 2026. Comparative efficacy and safety of ursodeoxycholic acid, fibrates, and combination therapy in primary biliary cholangitis: an umbrella meta-analysis of meta-analyses. Front Pharmacol (2026)

Nursoy M, et al. 2026. Systemic sclerosis and primary biliary cholangitis: a systematic review of case-control studies comparing isolated and overlapping disease phenotypes. J Scleroderma Relat Disord (2026)

Zhang J, et al. 2026. High Prevalence of Sarcopenia in Noncirrhotic Women With Primary Biliary Cholangitis: A Comparative Study of Clinical Characteristics and Risk Factors. Gastroenterol Res Pract (2026)

Bian S, et al. 2026. A segregating PTK2B variant in a primary biliary cholangitis (PBC) family induces PBC-like autoimmune features in knock-in mice. Cell Biosci (Jun 2026)

Del Barrio M, et al. 2026. Steatotic Liver Disease at Primary Biliary Cholangitis Diagnosis: Association With Ursodeoxycholic Acid Response and Outcomes. Liver Int (Jul 2026)

Rato B, et al. 2026. MRI periportal halo sign as a diagnostic trigger in AMA-negative primary biliary cholangitis. BMJ Case Rep (Jun 2026)

Wong RJ, et al. 2026. Up to 1 in 4 Veterans With Primary Biliary Cholangitis May Have Cirrhosis by the Time of Its Diagnosis. Gastro Hep Adv (2026)

Andrzejuk A, et al. 2026. Osteoporosis in primary biliary cholangitis: from cholestasis to fracture prevention. Clin Exp Hepatol (Mar 2026)

Lin Y, et al. 2026. Genetic mechanisms of primary biliary cholangitis and its association with immune cells using mendelian randomization and biological annotation. Medicine (Baltimore) (May 2026)

Li B, et al. 2026. Fenofibrate add-on therapy improves transplant-free survival in primary biliary cholangitis patients. Eur J Gastroenterol Hepatol (Jul 2026)

Su S, et al. 2026. Fenofibrate discontinuation and the association with clinical outcomes in primary biliary cholangitis patients receiving combination therapy. Int J Clin Pharm (Aug 2026)

Tirado Escuder A, et al. 2026. Persistent isolated AST elevation due to macro-AST in a patient with suspected primary biliary cholangitis. Med Clin (Barc) (May 2026)

Huang Z, et al. 2026. Novel Mechanistic Insights into Primary Biliary Cholangitis: From Pathogenesis to Mesenchymal Stem Cell-Mediated Repair. Biomedicines (May 2026)

, . 2026. EASL-AASLD Delphi consensus statement on surrogate endpoints and real-world evidence in primary biliary cholangitis. J Hepatol (May 2026)

Li H, et al. 2026. Mechanisms linking primary biliary cholangitis and osteoporosis: A combined clinical and molecular analysis. Medicine (Baltimore) (May 2026)

Shang C, et al. 2026. Multilevel Exploration of Shared Genetic Architecture Between Primary Biliary Cholangitis and Four Autoimmune Diseases. Endocr Metab Immune Disord Drug Targets (May 2026)

Bowlus CL, et al. 2026. Evolving Concepts of Treatment Targets for Primary Biliary Cholangitis: A Global Perspective. Am J Gastroenterol (May 2026)

Trivedi PJ, et al. 2026. Can we cure primary biliary cholangitis? Curr Opin Immunol (Jun 2026)

Gerussi A, et al. 2026. Definition, diagnosis, and treatment of primary biliary cholangitis - autoimmune hepatitis (PBC-AIH) variant: An international expert delphi consensus. Hepatology (May 2026)

Vierling JM, et al. 2026. Reply: Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis. Hepatol Commun (Jun 2026)

Chung AH, et al. 2026. Symptom burden and treatment patterns in primary biliary cholangitis: A systematic review and meta-analysis. Hepatol Commun (Jun 2026)

Granito A, et al. 2026. Primary biliary cholangitis: current insights and novel therapies. Expert Rev Clin Immunol (May 2026)

Chen PT, Chen HW. 2026. Reply to "Comment on 'Risk of colon polyps and colorectal cancer in primary biliary cholangitis, a population-based retrospective cohort study in Taiwan'". J Formos Med Assoc (May 2026)

Sohal A, et al. 2026. New therapies for primary biliary cholangitis. Hepatol Int (Jun 2026)

Zhu B, et al. 2026. Molecular mechanisms underlying T cell subset imbalance and precision therapeutic targets in primary biliary cholangitis. Front Pharmacol (2026)

Chen J, et al. 2026. Serum matrix metalloproteinase-7 as a diagnostic and prognostic biomarker in primary biliary cholangitis. Front Med (Lausanne) (2026)

Radice R, et al. 2026. The Role of Laboratory Markers in Primary Biliary Cholangitis: A Clinical Review and a Case Report. Biomedicines (Apr 2026)

Fan Q, Xiong DH. 2026. Comment on "Risk of colon polyps and colorectal cancer in primary biliary cholangitis, a population-based retrospective cohort study in Taiwan". J Formos Med Assoc (Apr 2026)

Alhaddad O, et al. 2026. Double-barreled drug-induced liver injury and the unmasking of latent primary biliary cholangitis: A case of amoxicillin-clavulanate and warfarin interaction. Arab J Gastroenterol (Apr 2026)

Ogata T, et al. 2026. Dendriform pulmonary ossification in fibrosing interstitial lung disease with primary biliary cholangitis. BMJ Case Rep (Apr 2026)

Wang X, et al. 2026. Clinicopathological features of non-cirrhotic portal fibrosis in primary biliary cholangitis: a 15-year experience at a tertiary referral center. Front Med (Lausanne) (2026)

Ooi QX, et al. 2026. Population Pharmacokinetics and Pharmacokinetics-Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary Cholangitis. CPT Pharmacometrics Syst Pharmacol (May 2026)

Angulugaha Gamage CMA, et al. 2026. Antimitochondrial Antibody-Negative Primary Biliary Cholangitis: A Diagnostic Challenge in a Sri Lankan Patient. Cureus (Mar 2026)

Berro M, et al. 2026. Antimitochondrial Antibody-Negative Primary Biliary Cholangitis in a Patient with a History of Colon Cancer and Chemotherapy: A Case Report. Avicenna J Med (Jan 2026)

Caines A, et al. 2026. Author Response to "Comment on Prediagnosis Alkaline Phosphatase and Antimitochondrial Antibody Positivity Vary by Race/Ethnicity Among Patients With Primary Biliary Cholangitis". J Gastroenterol Hepatol (Jun 2026)

Liu HL, et al. 2026. Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Reply. Aliment Pharmacol Ther (Jul 2026)

Jones D, et al. 2026. Network meta-analysis: relative clinical efficacy and safety of elafibranor versus seladelpar as second-line treatment for patients with primary biliary cholangitis. J Comp Eff Res (May 2026)

Ruiu A, et al. 2026. From unmet needs to new possibilities: PPAR-targeted therapies in the journey of people living with Primary Biliary Cholangitis. Eur J Intern Med (Apr 2026)

. 2026. Correction to "Characterisation and Clinical Relevance of Tertiary Lymphoid Structures in Primary Biliary Cholangitis". Liver Int (May 2026)

Cheng JS, et al. 2026. Medical Costs Increase Over Time for Primary Biliary Cholangitis Patients: A 20-Year Population-Based Study. Hepatol Res (Apr 2026)

Werner E, et al. 2026. A Nationwide Assessment of Anticholestatic Therapy Uptake in Patients With Primary Biliary Cholangitis: Opportunities for Optimisation. Aliment Pharmacol Ther (Jul 2026)

Beuers U, et al. 2026. Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis. Hepatol Commun (May 2026)

Gordon SC, et al. 2026. Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies. Hepatol Commun (May 2026)

Antal-Szalmás P, et al. 2026. Autoantibodies in the diagnostics, prognostics and follow-up of primary biliary cholangitis. J Transl Autoimmun (Jun 2026)

Song Y, et al. 2026. Breaking the metabolo-immune cycle in primary biliary cholangitis for therapeutic benefit. Front Immunol (2026)

Luo J, et al. 2026. [Impact of anti-gp210 and anti-centromere antibody dual positivity on clinical prognosis in patients with primary biliary cholangitis: risk analysis and establishment of response criteria]. Zhonghua Gan Zang Bing Za Zhi (Mar 2026)

Wang W, et al. 2026. Correction: Clinical outcomes and early- prognostic biomarkers of primary biliary cholangitis with ductopenia. Front Immunol (2026)

Gao A, et al. 2026. Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Aliment Pharmacol Ther (Jul 2026)

Levy C, et al. 2026. Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE. Liver Int (May 2026)

Levy C, et al. 2026. Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial. Aliment Pharmacol Ther (Jul 2026)

Ruan F, et al. 2026. Ocular surface characteristics and dry eye symptoms in primary biliary cholangitis patients complicated with seasonal allergic conjunctivitis. Int J Ophthalmol (2026)

Walia N, et al. 2026. The impact of male sex on outcomes in primary biliary cholangitis. Sci Rep (Mar 2026)

Schattenberg JM, et al. 2026. Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis. Aliment Pharmacol Ther (May 2026)

Gainutdin A, et al. 2026. Clinical and Demographic Features of Primary Biliary Cholangitis in Kazakhstan. Diseases (Mar 2026)

Xu Z, et al. 2025. Identification of secretory protein related biomarkers for primary biliary cholangitis based on machine learning and experimental validation. Open Life Sci (2025)

Thalassinos E, et al. 2026. Abnormalities of liver sinusoidal endothelial cells in primary biliary cholangitis. World J Exp Med (Mar 2026)

Lu W, et al. 2026. Hsa_circ_0000711 can serve as a novel biomarker for primary biliary cholangitis by promoting disease progression through the regulation of miR-185-5p and NFATc3. RNA Biol (Dec 2026)

Martins A, et al. 2026. Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis. Aliment Pharmacol Ther (May 2026)

García-Marmolejo JP, et al. 2026. Geographic distribution and demographic patterns of primary biliary cholangitis and autoimmune hepatitis in Colombia: a national population-based administrative study (2018-2024). Ann Gastroenterol (2026)

Dalekos GN, et al. 2026. Consensus statements of the Hellenic Autoimmune Liver Diseases Study Group on the diagnosis and current management of primary biliary cholangitis. Ann Gastroenterol (2026)

. 2026. Correction to "Trends in Primary Biliary Cholangitis: Prospective Cohort Study From the European Reference Network Registry (R-LIVER)". United European Gastroenterol J (Mar 2026)

Tana MM, Hirschfield GM. 2026. Primary Biliary Cholangitis and Prognostic Models-Reply. JAMA (Apr 2026)

(Facebook is for Irish PBC patients only)

Recent News

URSO Calculator

Mar 27th, 2026
PBC Ireland joins the PBC PAG with United Liver

Mar 17th, 2026
PBC Ireland partners with C-PATH

Mar 7th, 2026
PBC Good Care Guide Launched

Feb 4th, 2026
New publication alert in TAIRD!

Jan 1st, 2026
PBC Ireland commences collaboration with C-PATH

Jan 17th, 2026
PBC Ireland to present at Irish Liver Foundation @ Royal College of Surgeons, Ire.

Jan 15th, 2026
PBC Ireland launches their Patient Clinic Visit Questionnaire.

Jul 27th, 2025
The PBC Ireland Patient Registry is now LIVE!

Jul 26th, 2025
PBC Ireland will attend Global Liver Institute's A3 Program in Washington, DC

May 8th, 2025
PBC Ireland Launched!

Publications(100 publications from PubMed)

Recent News

Publications
(100 publications from PubMed)